IGC Pharma (IGC) Q1 2026 earnings summary

Executive summary

• Focused on developing therapeutics for neuropsychiatric and neurodegenerative disorders, especially Alzheimer's disease, with lead candidate IGC-AD1 in Phase 2 CALMA trial for agitation in Alzheimer's dementia.

• Pipeline includes early-stage assets (TGR-63) and AI-driven MINT-AD platform for risk stratification and assessment in Alzheimer's disease.

• Revenue is derived from wellness and lifestyle products and white-label services, not from pharmaceutical sales.

• Operations funded by equity, debt, and strategic capital allocation; continued operating losses expected as clinical programs advance.

Financial highlights

• Revenue for Q1 2026 was $317K, down 4% year-over-year; gross margin declined to 17% from 47% due to higher cost of revenue and product mix.

• Net loss increased to $2.4M from $1.2M year-over-year, driven by higher SG&A and R&D expenses.

• Cash and cash equivalents fell to $207K from $900K at year-end 2025, mainly due to $1.2M in operating cash outflows.

• Working capital deficit widened to $1.7M from $366K at year-end 2025.

Outlook and guidance

• Management expects continued operating losses and negative cash flow as clinical and research programs progress.

• Current cash, investments, and a $12M credit facility are expected to support operations for at least the next 12 months, but additional financing may be needed.

• Focus remains on completing the CALMA trial, advancing MINT-AD and AHA platforms, and seeking non-dilutive grants.